|  |  |
| --- | --- |
| **A drawing of a brain  Description automatically generated with medium confidenceGraphical user interface, application  Description automatically generatedPARTICIPANT SHORT INFORMATION SHEET FOR RELATIVES**    **(Final Version 1.1 24/03/2023)**  **Title of Study:** TICH-3 **EU CTR Number: 2022-500587-35-01**  **Name of Researcher**:  **Name of Participant:** | |
|  | **What is this about?**   * We want to know if you would like your relative to take part in a research study to test a drug called tranexamic acid * Taking part in the study is voluntary- your relative does not need to take part   **Why are we asking your relative to take part in this study?**   * Your relative has had a stroke caused by bleeding in the brain this is known as intracerebral haemorrhage (ICH). * Stroke is an emergency – it is important that treatment is given as soon as possible   **What is the study testing?**   * We want to know if the drug tranexamic acid reduces the bleeding in this type of stroke and may reduce the severity of injury caused by the stroke. * **Tranexamic acid is approved for use in other emergency medical conditions to stop bleeding** but we do not know for certain if it helps recovery after stroke due to bleeding in the brain. |
| PLACEBO  TRANEXAMIC  ACID | **If your relative participates: study treatment**   * Your relative will receive all the care and treatments for stroke they would normally receive. * The study will also involve giving you a drip for 8 hours. This will contain tranexamic acid or no drug, known as placebo. * Which drip your relative is given is decided by chance (like flipping a coin) – this is called randomisation * Because bleeding is an emergency and needs speedy treatment, after the brain scan, we will ask for verbal permission and then ask for written consent afterwards. |
|  | **Risks**   * Tranexamic acid is used in other emergency medical conditions to stop bleeding and appears safe * Mild side effects: diarrhoea, low blood pressure and dizziness - all can be easily treated. * Very rarely, but more serious side effects could be blood clots in the legs (DVT) or lungs (PE) but we will monitor very closely for this. |
|  | **180 days after your stroke:**   * Your relative will receive a questionnaire in the post asking how you are. * If your relative cannot complete the questionnaire by themselves, a researcher can call them to complete it together * If your relative is not well enough to talk, we will ask you or other family relative or GP to complete the questionnaire. |
|  | **During the study:**   * If you have any questions, please ask. * You may opt to withdraw your relative from the study at any time. This will not affect their care at any time. * All the information we hold about your relative will be kept in the strictest confidence. |

**Further information and contact details**

**Trials Office**

Nottingham Stroke Trials Unit

D floor South block, Room 2123

Queens Medical Centre

University of Nottingham

NG7 2UH

Tel: 0115 823 1782

Email: MS-TICH-3-inter@nottingham.ac.uk